IDEXX Laboratories Touts 'Exceptional' Q4, Targets 8%-10% 2026 Growth at BofA Summit

Executives highlight innovation-driven momentum and outline key priorities for the year ahead.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company's 'exceptional' fourth-quarter results and outlined key priorities for 2026 during Bank of America's 2026 Animal Health Summit. The discussion featured Executive Vice President and CFO Andrew Emerson and Executive Vice President Mike Lane, who leads global reference laboratories, diagnostic solutions, and information technology.

Why it matters

IDEXX is a major player in the animal health diagnostics market, and its performance and outlook provide insights into trends and opportunities in the broader veterinary industry. The company's focus on innovation, including new diagnostic platforms and capabilities, could shape the future of pet care and help drive growth.

The details

Emerson said IDEXX delivered approximately 12% organic revenue growth in the fourth quarter, supported by 'top-line, double-digit gains' and 'strong operating margin improvement.' He said this helped the company achieve double-digit organic growth for 2025 overall, including about 90 basis points of comparable operating margin improvement year over year. Executives emphasized the role of innovation, such as the inVue Dx Analyzer and Cancer Dx, in accelerating growth. For 2026, IDEXX is planning for 8% to 10% organic growth in companion animal group (CAG) diagnostic recurring revenue, with a midpoint of about 9%, and about 5,500 inVue Dx instrument placements.

  • IDEXX delivered approximately 12% organic revenue growth in the fourth quarter of 2025.
  • IDEXX achieved double-digit organic growth for 2025 overall, including about 90 basis points of comparable operating margin improvement year over year.
  • IDEXX is planning for 8% to 10% organic growth in companion animal group (CAG) diagnostic recurring revenue in 2026, with a midpoint of about 9%.
  • IDEXX is planning for about 5,500 inVue Dx instrument placements in 2026.

The players

IDEXX Laboratories

A global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets, headquartered in Westbrook, Maine.

Andrew Emerson

Executive Vice President and CFO of IDEXX Laboratories.

Mike Lane

Executive Vice President of IDEXX Laboratories, leading global reference laboratories, diagnostic solutions, and information technology.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

IDEXX's focus on innovation, including new diagnostic platforms and capabilities, is driving growth and positioning the company to capitalize on trends in the veterinary industry. The company's strong performance and forward-looking plans suggest it remains a leader in the animal health diagnostics market.